Literature DB >> 26309566

Role of IL-6 in the invasiveness and prognosis of glioma.

Yongzhi Shan1, Xin He2, Wei Song3, Dong Han3, Jianxing Niu4, Jianzhen Wang4.   

Abstract

IL-6 is a cytokine secreted by glioma cells and plays an important role in the tumor growth. However, the impact of IL-6 on the invasiveness and prognosis of glioma is still unclear. In this study, immunohistochemistry was performed to determine the expression of IL-6 in 86 glioma tissues, and ELISA to measure IL-6 in the serum and cerebrospinal fluid (CSF) of these patients. Results showed, as ccompared with normal controls, the IL-6 in the glioma, CSF and serumincreased remarkably, and increased with the elevation of glioma grade. In addition, IL-6 in the supernatant was also detectable in glioma cell lines U251, U87, A172 and T98G. Transwell invasion assay showed that the invasiveness of glioma U87 cells and U251 cells increased remarkably after exogenous IL-6 treatment. Survival analysis indicated higher IL-6 before surgery and significantly reduction in IL-6 after operation in the serum and CSF predicted a poor prognosis. Thus, we speculate that, the poor prognosis of glioma is related to the IL-6 autocrine in the glioma and the IL-6 induced tumor growth and invasion. IL-6 may serve as a therapeutic target for glioma patients and IL-6 in the CSF and serum of glioma may be used to predict the prognosis of these patients.

Entities:  

Keywords:  Glioma; IL-6; cerebrospinal fluid

Year:  2015        PMID: 26309566      PMCID: PMC4538008     

Source DB:  PubMed          Journal:  Int J Clin Exp Med        ISSN: 1940-5901


  19 in total

Review 1.  IL-6 signaling in autoimmunity, chronic inflammation and inflammation-associated cancer.

Authors:  Markus F Neurath; Susetta Finotto
Journal:  Cytokine Growth Factor Rev       Date:  2011-03-05       Impact factor: 7.638

2.  Interferon-gamma increases IL-6 production in human glioblastoma cell lines.

Authors:  M Hotfilder; H Knupfer; G Mohlenkamp; P Pennekamp; M Knupfers; S Van Gool; J E Wolff
Journal:  Anticancer Res       Date:  2000 Nov-Dec       Impact factor: 2.480

3.  NCCN Task Force report: Evaluating the clinical utility of tumor markers in oncology.

Authors:  Phillip G Febbo; Marc Ladanyi; Kenneth D Aldape; Angelo M De Marzo; M Elizabeth Hammond; Daniel F Hayes; A John Iafrate; R Kate Kelley; Guido Marcucci; Shuji Ogino; William Pao; Dennis C Sgroi; Marian L Birkeland
Journal:  J Natl Compr Canc Netw       Date:  2011-11       Impact factor: 11.908

4.  IL-6 and Stat3 are required for survival of intestinal epithelial cells and development of colitis-associated cancer.

Authors:  Sergei Grivennikov; Eliad Karin; Janos Terzic; Daniel Mucida; Guann-Yi Yu; Sivakumar Vallabhapurapu; Jürgen Scheller; Stefan Rose-John; Hilde Cheroutre; Lars Eckmann; Michael Karin
Journal:  Cancer Cell       Date:  2009-02-03       Impact factor: 31.743

5.  IL-6 involvement in epithelial cancers.

Authors:  Zachary T Schafer; Joan S Brugge
Journal:  J Clin Invest       Date:  2007-12       Impact factor: 14.808

6.  Bradykinin stimulates IL-6 production and cell invasion in colorectal cancer cells.

Authors:  Guojun Wang; Yanwei Ye; Xiefu Zhang; Junmin Song
Journal:  Oncol Rep       Date:  2014-07-30       Impact factor: 3.906

7.  Clinical Neuropathology Practice News 4-2012: levels of evidence for brain tumor biomarkers.

Authors:  Anna Sophie Berghoff; Harald Stefanits; Harald Heinzl; Matthias Preusser
Journal:  Clin Neuropathol       Date:  2012 Jul-Aug       Impact factor: 1.368

8.  Role of MMP-2 in the regulation of IL-6/Stat3 survival signaling via interaction with α5β1 integrin in glioma.

Authors:  D Kesanakurti; C Chetty; D H Dinh; M Gujrati; J S Rao
Journal:  Oncogene       Date:  2012-02-20       Impact factor: 9.867

9.  NF-κB-induced IL-6 ensures STAT3 activation and tumor aggressiveness in glioblastoma.

Authors:  Braden C McFarland; Suk W Hong; Rajani Rajbhandari; George B Twitty; G Kenneth Gray; Hao Yu; Etty N Benveniste; Susan E Nozell
Journal:  PLoS One       Date:  2013-11-11       Impact factor: 3.240

10.  Tumor-associated macrophage-derived IL-6 and IL-8 enhance invasive activity of LoVo cells induced by PRL-3 in a KCNN4 channel-dependent manner.

Authors:  Heyang Xu; Wei Lai; Yang Zhang; Lu Liu; Xingxi Luo; Yujie Zeng; Heng Wu; Qiusheng Lan; Zhonghua Chu
Journal:  BMC Cancer       Date:  2014-05-10       Impact factor: 4.430

View more
  32 in total

1.  Resistance to cytotoxicity and sustained release of interleukin-6 and interleukin-8 in the presence of decreased interferon-γ after differentiation of glioblastoma by human natural killer cells.

Authors:  Anna K Kozlowska; Han-Ching Tseng; Kawaljit Kaur; Paytsar Topchyan; Akihito Inagaki; Vickie T Bui; Noriyuki Kasahara; Nicholas Cacalano; Anahid Jewett
Journal:  Cancer Immunol Immunother       Date:  2016-07-20       Impact factor: 6.968

2.  P2Y14 receptor activation decreases interleukin-6 production and glioma GL261 cell proliferation in microglial transwell cultures.

Authors:  Marjorie A Curet; Jyoti J Watters
Journal:  J Neurooncol       Date:  2017-11-30       Impact factor: 4.130

3.  Prognostic role of high sensitivity C-reactive protein and interleukin-6 in glioma and meningioma patients.

Authors:  Adomas Bunevicius; Andrius Radziunas; Sarunas Tamasauskas; Arimantas Tamasauskas; Edwards R Laws; Giorgio Iervasi; Robertas Bunevicius; Vytenis Deltuva
Journal:  J Neurooncol       Date:  2018-02-19       Impact factor: 4.130

4.  Glioblastoma-Derived IL6 Induces Immunosuppressive Peripheral Myeloid Cell PD-L1 and Promotes Tumor Growth.

Authors:  Jonathan B Lamano; Jason Balquidera Lamano; Yuping D Li; Joseph D DiDomenico; Winward Choy; Dorina Veliceasa; Daniel E Oyon; Shayan Fakurnejad; Leonel Ampie; Kartik Kesavabhotla; Rajwant Kaur; Gurvinder Kaur; Dauren Biyashev; Dusten J Unruh; Craig M Horbinski; C David James; Andrew T Parsa; Orin Bloch
Journal:  Clin Cancer Res       Date:  2019-03-01       Impact factor: 12.531

Review 5.  The road-map for establishment of a prognostic molecular marker panel in glioma using liquid biopsy: current status and future directions.

Authors:  Richa Shrivastava; Puneet Gandhi; Ragini Gothalwal
Journal:  Clin Transl Oncol       Date:  2022-06-02       Impact factor: 3.340

6.  Commentary: Evaluating potential glioma serum biomarkers, with future applications.

Authors:  Michael Goutnik; Brandon Lucke-Wold
Journal:  World J Clin Oncol       Date:  2022-05-24

7.  TERT Genetic Mutations as Prognostic Marker in Glioma.

Authors:  Peiliang Geng; Xiaoxin Zhao; Juanjuan Ou; Jianjun Li; Rina Sa; Houjie Liang
Journal:  Mol Neurobiol       Date:  2016-05-20       Impact factor: 5.590

8.  Blood-Based Biomarkers for Glioma in the Context of Gliomagenesis: A Systematic Review.

Authors:  Hamza Ali; Romée Harting; Ralph de Vries; Meedie Ali; Thomas Wurdinger; Myron G Best
Journal:  Front Oncol       Date:  2021-06-04       Impact factor: 6.244

9.  Regulation of autophagy inhibition and inflammatory response in glioma by Wnt signaling pathway.

Authors:  Tongxin Wang; Zhixia Chen; Wei Zhang
Journal:  Oncol Lett       Date:  2017-09-29       Impact factor: 2.967

10.  Impact of mesenchymal stem cells' secretome on glioblastoma pathophysiology.

Authors:  Joana Vieira de Castro; Eduardo D Gomes; Sara Granja; Sandra I Anjo; Fátima Baltazar; Bruno Manadas; António J Salgado; Bruno M Costa
Journal:  J Transl Med       Date:  2017-10-02       Impact factor: 5.531

View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.